A PHASE 2A, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY & EFFICACY OF A SINGLE DOSE OF RABI-767 ADMIN BY ENDOSCOPIC ULTRASOUND-GUIDED PERIPANCREATIC INJ + SOC VS SOC ONLY IN PARTICIPANTS WITH PREDICTED SEVERE ACUTE PANCREATITIS

Registry ID

RABI-767-201

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PANAFINA, INC.

Last update

2025-06-04

Conditions

• PANCREATITIS

View on source registry